# Pharos iBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharos-ibio-co

- Industry: Biotechnology
- Headquarters: Anyang, South Korea
- Website: www.pharosibt.com
- Total disclosed funding: $36M
- Latest round: Series C (Jun 16, 2021)
- Investors on record: 14

## About

Based in Anyang-si, South Korea, and founded in 2016, Pharos iBio Co., Ltd. engages in the development of new drugs specializing in the treatment of rare incurable diseases based on big data and AI technologies. In 2016, Pharos iBio Co., Ltd. signed a contract for exclusive development of Acute Myeloid Lekemia (AML) therapeutics technology. In 2017, the company started preclinical study of PHI-101. In 2019, TGA in Australia granted PHI-101 phase 1 clinical trials. In 2020, the company engaged in the joint research and technology agreement with Yonsei University health system and established a subsidiary in USA. The company's CEO is Jeonghyeok Yun. It has overseas subsidiaries in the USA and Australia. In July 2023, Pharos iBio Co., Ltd. raised KRW 19.6 billion in an IPO, selling 1.4 million shares at KRW 14,000 per share, within the expected price range of KRW 14,000 and KRW 18,000 on the KOSDAQ.

Pharos iBio Co., Ltd. engages in R&D of new drug treatments for rare incurable disease using AI new drug development platform. The company calls its platform as Chemivesre platform, which can be used in all fields of discovery in the new drug development stage. Pharos iBio Co., Ltd. has developed several different kinds of platforms such as PHI-101-001, a treatment drug for refractory/recurrent Acute Myelogenous Leukemia (AML), PHI-101-002, a treatment for platinum-resistant/refractory ovarian cancer, etc.

For its future plans, Pharos iBio Co., Ltd. plans to be listed in the KOSDAQ by the end of 2021.

## Funding rounds

- Series C, Jun 16, 2021, $16M — Industrial Bank of Korea, Solidus Investment, Company K Partners, UTC Investment, LSK Investment, Intops Investment, Prodigy Investment, KDB Capital
- Series B, Mar 19, 2020, $13M — Korea Development Bank, Korea Investment & Securities, Korea Investment Partners, DSC Investment, Company K Partners, Mirae Asset Venture Investment
- Series A, Aug 8, 2018, $6.6M — Korea Investment Partners, DSC Investment, IMM Investment, Mirae Asset Venture Investment

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A, Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A, Series B
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series B, Series C
- Industrial Bank of Korea — Series C
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series C
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series C
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series C
- Intops Investment (https://capitalatlas.ai/funds/intops-investment) — Series C
- Prodigy Investment (https://capitalatlas.ai/funds/prodigy-investment) — Series C
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series C